



Only IGRA cleared by FDA
for ages two and up.¹



FOR
EVERYONE
OVER THE
AGE OF
TWO.

T-SPOT[®] TB

A MOMENT OF TRUTH

T-SPOT®.TB

The only IGRA cleared by the FDA for your patients two and older, including your BCG-vaccinated patients, healthy patients and patients with compromised immune systems.¹



Did you know?

Samples can be drawn using a butterfly needle without the use of a purge tube. Many butterfly needles have the same needle gauge as the tuberculin skin test (TST).²

EASY

The younger the patient, the smaller the blood sample¹

ACCURATE

Only TB test with both sensitivity and specificity exceeding 95% and no cross-reaction with the BCG-vaccine¹

ACCESSIBLE

Available through all Quest Diagnostics® Patient Service Centers and numerous regional laboratory partners

Reduce unnecessary return visits and treatments

Based on a peer-reviewed study of > 3,600 children under the age of 15, switching from the TST to an interferon-gamma release assay (IGRA), like the T-SPOT.TB test, could reduce unnecessary chest x-rays and treatments by up to two-thirds in non-US born children.³

In another study of > 645,000 samples, the T-SPOT.TB test had an invalid rate of rate of < 1%.⁴

- ✓ Reduced office visits
- ✓ A result you and your patient can trust



Reduce unnecessary chest x-rays and treatments by 2/3



Invalid rate of < 1%

1 tube, 1 visit and low blood volume requirements¹

- Children 10 years old and over: 1 sodium or lithium heparin 6 mL tube
- Children > 2 or < 10 years old: 1 sodium or lithium heparin 4 mL tube
- Children up to 2 years old: 1 sodium or lithium heparin 2 mL pediatric tube*

Accurate across patient populations¹

The T-SPOT.TB test is also the only IGRA without a warning or limitation in its package insert for screening immunocompromised patients.^{1,5}

Guidelines support IGRA testing

Guideline	Recommendation by population
American Academy of Pediatrics (AAP) 2018 ⁶	IGRAs are indicated in ages 2 and up, and preferred in children who are BCG-vaccinated or unlikely to return to have TST read
Infectious Diseases Society of America (IDSA), American Thoracic Society (ATS) and Centers for Disease Control (CDC), 2017 ⁷	Ages 5 and up, IGRAs indicated, especially in those who are not high risk for progressing to active TB
CDC Civil Surgeons 2018 ⁸	IGRAs required in ages 2 and up <ul style="list-style-type: none"> • All applicants 2 years or older must have an IGRA • TST cannot be used as a substitute for IGRA testing

In the fight against TB, the truth has consequences

Every year 10 million people become ill with TB – and 1.5 million die.⁹ That number includes 230,000 child deaths.¹⁰ But you can fight back – if you make the most of every TB test to protect the patient and take tuberculosis out of the community. The T-SPOT.TB test is designed to maximize testing as a weapon against the TB epidemic. With forensic attention to detail, it removes causes of doubt other tests leave in, to give answers you can trust^{1, 11, 12}.

It's not just a test; it's a moment of truth for TB.

Learn more by visiting [TSPOT.COM/pediatrics](https://www.oxfordimmunotec.com/pediatrics)

REFERENCES:

1. Oxford Immunotec. T-SPOT.TB Package Insert PI-TB-US-0001 V8. Abingdon, UK. September 2020.
2. Dacso CC. Skin Testing for Tuberculosis. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 47. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK369>
3. Ahmed A, Fend PJ, Gaensbauer JT, Reves RR, Khurana R, Salcedo K, Punnoose R, Katz DJ, for the TUBERCULOSIS EPIDEMIOLOGIC STUDIES CONSORTIUM. Interferon- γ Release Assays in Children <15 Years of Age. *Pediatrics*. 2020;145(1):e20191930.
4. Rego K, Pereira K, MacDougall J, Cruikshank W. Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off point. *Tuberculosis*. 2018;108:178-185. doi:10.1016/j.tube.2017.12.005.
5. Qiagen. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. 1095849 Rev. 06. November 2019.
6. American Academy of Pediatrics. Red Book®: 2018–2021 Report of the Committee on Infectious Diseases. 829-853.
7. Lewinsohn, D.M. et al. (2017) Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention.
8. Tuberculosis Technical Instructions for Civil Surgeons. Centers for Disease Control and Prevention. <https://www.cdc.gov/immigrantrefugeehealth/exams/ti/civil/tuberculosis-civil-technical-instructions.html> Last reviewed September 19, 2019. Accessed August 12, 2020
9. World Health Organization. Global tuberculosis report 2019. License: CC BY-NC-SA 3.0 IGO
10. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. *The Lancet Global Health*. 2017;5(9). doi:10.1016/s2214-109x(17)30289-9.
11. Lalvani A, Pareek M. Interferon gamma release assays: principles and practice. *Enferm Infecc Microbiol Clin*. 2009. doi:10.1016/j.eimc.2009.05.012 – which has a chart showing the steps taking in T-SPOT.TB test vs QFT.
12. Wong. Effect of immunosuppressive therapy on interferon gamma release assay for LBTI screening in patients with autoimmune diseases: a systematic review and meta-analysis. *Thorax*. December 2015. <http://thorax.bmj.com/content/thoraxjnl/71/1/64.full.pdf>. Accessed July 21, 2017

* Limitation: The performance of the T-SPOT.TB test has not been adequately evaluated with specimens from individuals younger than the age of 2.

T-SPOT®.TB

 **Oxford
Immunotec**

T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd.
Quest Diagnostics is a registered trademark of Quest Diagnostics.
© 2020 Oxford Immunotec. All rights reserved.
TB-US-BRCH-MPN391-0001 V1